<DOC>
	<DOCNO>NCT00956007</DOCNO>
	<brief_summary>RATIONALE : Giving radiation therapy use 3-dimensional ( 3-D ) image tumor help focus thin beam radiation directly tumor , give radiation therapy high dos shorter period time , may kill tumor cell few side effect . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . It yet know whether radiation therapy effective give alone together cetuximab treat patient head neck cancer remove surgery . PURPOSE : This randomized phase III trial study radiation therapy see well work compare radiation therapy give together cetuximab treat patient undergone surgery locally advanced head neck cancer .</brief_summary>
	<brief_title>Radiation Therapy With Without Cetuximab Treating Patients Who Have Undergone Surgery Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether addition cetuximab postoperative intensity-modulated radiotherapy ( IMRT ) improve overall survival ( OS ) patient locally advance squamous cell carcinoma head neck intermediate risk follow surgery . Secondary - Assess impact addition cetuximab postoperative IMRT disease-free survival ( DFS ) patient . - Assess impact addition cetuximab postoperative IMRT acute late dysphagia , xerostomia , skin toxicity , toxicity accord common Toxicity Criteria Adverse Effects ( CTCAE ) , v. 4 relationship patient-reported outcome 3 , 12 , 24 month . - Analyze tumor epidermal growth factor receptor ( EGFR ) , specifically extent EGFR overexpression immuno-histochemistry ( IHC ) FISH analysis , EGFRvIII expression , well association assay data OS DFS . - Analyze tumor human papillomavirus ( HPV ) infection ( define situ hybridization ) , specifically , within cohort patient oropharynx cancer , perform exploratory analysis impact HPV DFS OS patient subset . - Analyze tumor DNA TP53 mutation predictor response cetuximab prognosis . - Analyze germline DNA polymorphic variant EGFR intron repeat predictor response cetuximab . Tertiary - Assess impact addition cetuximab postoperative IMRT loco-regional control . - Assess impact addition cetuximab postoperative IMRT patient-reported quality life , swallow , xerostomia , skin toxicity base head neck specific instrument , include Performance Status Scale Head Neck Cancer ( PSS-HN ) , Functional Assessment Cancer Therapy-Head &amp; Neck ( FACT-H &amp; N ) , University Michigan Xerostomia-Related Quality Life Scale ( XeQOLS ) , Dermatology Life Quality Index ( DLQI ) . - Assess impact addition cetuximab postoperative IMRT cost-utility analysis use EuroQol ( EQ-5D ) . - Evaluate utility image-guided radiotherapy ( IGRT ) mean enhance efficacy ( i.e. , loco-regional control ) IMRT reduce acute and/or late toxicity ( particularly xerostomia ) improve patient-reported outcome ( particularly XeQOLS score ) . - Retrospectively compare loco-regional control rate patient treat IMRT alone ( IGRT cetuximab ) similar patient treat external beam radiotherapy alone postoperative clinical trial Radiation Therapy Oncology Group ( RTOG ) -95 01 . OUTLINE : This multicenter study . Patients stratify accord clinical stage ( T2-3 v T4a ) , EGFR expression ( high [ ≥ 80 % cell stain positive ] v low [ &lt; 80 % cell stain positive ] v evaluable ) , primary site disease ( oral cavity v larynx v oropharynx p16+ v oropharynx p16- v oropharynx , p16 evaluable ) , use image-guided radiotherapy ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo intensity-modulated radiotherapy ( IMRT ) daily 5 day week 6 week absence disease progression unacceptable toxicity . - Arm II : Patients undergo IMRT arm I . Patients also receive cetuximab IV 1-2 hour weekly begin least 5 day prior start IMRT continue 4 week completion IMRT ( total 11 dos ) absence disease progression unacceptable toxicity . Quality life assess baseline 3 , 12 , 24 month . Tissue sample collect periodically laboratory analysis . After completion study treatment , patient follow 1 3 month , every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma ( include variant , verrucous carcinoma , spindle cell carcinoma , carcinoma otherwise specify ) head neck , include follow subtypes : Oral cavity Oropharynx Larynx Clinical stage T1 , N12 , M0 OR T24a , N02 , M0 disease base follow diagnostic workup within past 8 week : General history physical examination Radiation Oncologist and/or Medical Oncologist Chest xray chest CT scan ( without contrast ) chest CT/PET scan ( without contrast ) Must undergone gross total resection primary tumor curative intent within past 7 week surgical pathology demonstrate ≥ 1 follow criterion `` intermediate '' risk recurrence : Perineural invasion Lymphovascular invasion Single lymph node &gt; 3 cm ≥ 2 lymph node ( &lt; 6 cm ) ( extracapsular extension ) Close margin ( ) resection , define cancer extend within 5 mm surgical margin , and/or initially focally positive margin subsequently supersede intraoperative negative margin ( similarly , patient whose tumor focally positive margin main specimen negative margin reexcised sample region positive margin eligible ) Pathologically confirm T3 T4a primary tumor T2 oral cavity cancer &gt; 5 mm depth invasion No positive margin ( ) ( define tumor present cut ink edge tumor ) , nodal extracapsular extension , and/or gross residual disease surgery PATIENT CHARACTERISTICS : Zubrod performance status 01 Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 8.0 g/dL ( transfusion intervention allow ) Total bilirubin &lt; 2 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 time ULN Serum creatinine &lt; 2 time ULN OR creatinine clearance ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No invasive malignancy within past 3 year , except nonmelanomatous skin cancer previously treat carcinoma situ breast , oral cavity , cervix No simultaneous primary bilateral tumor No severe , active comorbidity , include follow : Unstable angina and/or congestive heart failure require hospitalization within past 6 month Transmural myocardial infarction within past 6 month Acute bacterial fungal infection require IV antibiotic time study registration Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy Idiopathic pulmonary fibrosis severe interstitial lung disease require oxygen therapy thought require oxygen therapy within past year Hepatic insufficiency result clinical jaundice and/or coagulation defect AIDS base current Centers Disease Control ( CDC ) definition Grade 34 electrolyte abnormality accord CTCAE , v. 4 , include follow : Serum calcium ( ionize adjust albumin ) &lt; 7 mg/dL &gt; 12.5 mg/dL* Glucose &lt; 40 mg/dL &gt; 250 mg/dL Magnesium &lt; 0.9 mg/dL &gt; 3 mg/dL* Potassium &lt; 3.0 mmol/L &gt; 6 mmol/L* Sodium &lt; 130 mmol/L &gt; 155 mmol/L* NOTE : *Despite intervention normalize level . No prior allergic reaction cetuximab PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior systemic chemotherapy antiepidermal growth factor ( EGF ) therapy cancer Prior chemotherapy antiEGF therapy different cancer allow No prior radiotherapy region study cancer would result overlap radiotherapy field No concurrent amifostine radioprotector No concurrent granulocyte colonystimulating factor erythropoietin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>tongue cancer</keyword>
</DOC>